Endoscopy 2019; 51(09): 836-842
DOI: 10.1055/a-0824-7067
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study

Marc Barthet
1   Aix Marseille Université, Service de Gastro-entérologie, Hôpital Nord, Marseille, France
Marc Giovannini
2   Endoscopy Unit, Institut Paoli Calmettes, Marseille, France
Nathalie Lesavre
3   Centre d’Investigation Clinique, Hôpital Nord, Marseille, France
Christian Boustiere
4   Service d’Hépato-gastroentérologie, Hôpital Saint-Joseph, Marseille, France
Bertrand Napoleon
5   Hôpital privé Jean Mermoz, Ramsay Générale de Santé, Lyon, France
Stéphane Koch
6   Department of Gastroenterology, CHRU Minjoz, Besançon, France
Mohamed Gasmi
1   Aix Marseille Université, Service de Gastro-entérologie, Hôpital Nord, Marseille, France
Geoffroy Vanbiervliet
7   Centre Hospitalier Universitaire de Nice, Hôpital L’Archet 2, Nice, France
Jean-Michel Gonzalez
1   Aix Marseille Université, Service de Gastro-entérologie, Hôpital Nord, Marseille, France
› Author Affiliations
TRIAL REGISTRATION: prospective multicenter study NCT02330497 at clinicaltrials.gov
Further Information

Publication History

submitted 21 June 2018

accepted after revision 12 November 2018

Publication Date:
22 January 2019 (online)


Background Pancreatic neuroendocrine tumors (NETs) and intraductal pancreatic mucinous neoplasia (IPMN) with worrisome features are surgically managed. Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) has recently been developed. The safety of EUS-RFA was the primary end point of this study, its efficacy the secondary end point.

Methods This was a prospective multicenter study that was planned to include 30 patients with a 1-year follow-up with either a NET < 2 cm or a pancreatic cystic neoplasm (PCN), either a branch duct IPMN with worrisome features or a mucinous cystadenoma (MCA). EUS-RFA was performed with an 18G RFA cooling needle.

Results 12 patients had 14 NETs (mean size 13.1 mm, range 10 – 20 mm); 17 patients had cystic tumors (16 IPMNs, 1 MCA; mean size 28 mm, range 9 – 60 mm). Overall three adverse events occurred (10 %), two of these in the first two patients (one pancreatitis, one small-bowel perforation). After these initial patients, modifications in the protocol resulted in a decrease in complications (3.5 %), with one patient having a pancreatic ductal stenosis. Among the 14 NETs, at 1-year follow-up 12 had completely disappeared (86 % tumor resolution), with three patients having a delayed response. Among the 17 PCNs, at 12 months, there were 11 complete disappearances and one diameter that decreased by > 50 % (significant response rate 71 %). All 12 mural nodules showed complete resolution.

Conclusions EUS-RFA of pancreatic NETs or PCNs is safe with a 10 % complication rate, which can be decreased by improved prophylaxis for the procedure.

  • References

  • 1 Farrell JJ. Prevalence, diagnosis and management of pancreatic cystic neoplasms: current status and future directions. Gut Liver 2015; 9: 571-589
  • 2 Tanaka M, Fernández-Del Castillo C, Kamisawa T. et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017; 17: 738-753
  • 3 Lee DW, Kim MK, Kim HG. Diagnosis of pancreatic neuroendocrine tumors. Clin Endosc 2017; 50: 537-545
  • 4 Sachs T, Pratt WB, Callery MP. et al. The incidental asymptomatic pancreatic lesion: nuisance or threat?. J Gastrointest Surg 2009; 13: 405-415
  • 5 Strosberg JR, Cheema A, Weber J. et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29: 3044-3049
  • 6 Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-1492
  • 7 Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. NEJM 2011; 364: 2128-2137
  • 8 Lakhtakia S. Therapy of pancreatic neuroendocrine tumors: fine needle intervention including ethanol and radiofrequency ablation. Clin Endosc 2017; 50: 546-551
  • 9 Chennat J. Current status of endoscopic ultrasound guided ablation techniques. Gastroenterology 2011; 140: 1403-1409
  • 10 Brugge WR, Lewandrowski K, Lee-Lewandrowski E. et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004; 126: 1330-1336
  • 11 Okabayashi T, Kobayashi M, Nishimori I. et al. Clinicopathological features and medical management of intraductal papillary mucinous neoplasms. J Gastroenterol Hepatol 2006; 21: 462-467
  • 12 Lakhtakia S, Seo D-W. Endoscopic ultrasonography-guided tumor ablation. Dig Endosc 2017; 29: 486-494
  • 13 Oh H-C, Seo DW, Lee TY. et al. New treatment for cystic tumors of the pancreas: EUS-guided ethanol lavage with paclitaxel injection. Gastrointest Endosc 2008; 67: 636-642
  • 14 DeWitt J, McGreevy K, Schmidt CM. et al. EUS-guided ethanol versus saline solution lavage for pancreatic cysts: a randomized, double-blind study. Gastrointest Endosc 2009; 70: 710-723
  • 15 Zacharoulis D, Lazoura O, Rountas C. et al. Experimental animal study of a novel radiofrequency endovascular occlusion device. Am J Surg 2011; 202: 103-109
  • 16 Sethi A, Ellrichmann M, Dhar S. et al. Endoscopic ultrasound-guided lymph node ablation with a novel radiofrequency ablation probe: feasibility study in an acute porcine model. Endoscopy 2014; 46: 411-415
  • 17 Kim HJ, Seo D-W, Hassanuddin A. et al. EUS-guided radiofrequency ablation of the porcine pancreas. Gastrointest Endosc 2012; 76: 1039-1043
  • 18 Mukewar S, Muthusamy VR. Recent advances in therapeutic endosonography for cancer treatment. Gastrointest Endosc Clin N Am 2017; 27: 657-680
  • 19 Kim J. Endoscopic ultrasound-guided treatment of pancreatic cystic and solid masses. Clin Endosc 2015; 48: 308-311
  • 20 McCarty TR, Rustagi T. New indications for endoscopic radiofrequency ablation. Clin Gastroenterol Hepatol 2018; 16: 1007-1017
  • 21 Slovak R, Ludwig JM, Gettinger SN. et al. Immuno-thermal ablations – boosting the anticancer immune response. J Immunother Cancer 2017; 5: 78
  • 22 Song TJ, Seo DW, Lakhtakia S. et al. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc 2016; 83: 440-443
  • 23 Arcidiacono PG, Carrara S, Reni M. et al. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc 2012; 76: 1142-1151
  • 24 Crinò SF, D’Onofrio M, Bernardoni L. et al. EUS-guided radiofrequency ablation (EUS-RFA) of solid pancreatic neoplasm using an 18-gauge needle electrode: feasibility, safety, and technical success. J Gastrointest Liver Dis 2018; 27: 67-72
  • 25 Lakhtakia S, Ramchandani M, Galasso D. et al. EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointest Endosc 2016; 83: 234-239
  • 26 Rossi S, Viera FT, Ghittoni G. et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas 2014; 43: 938-945
  • 27 Armellini E, Crinò SF, Ballarè M. et al. Endoscopic ultrasound-guided radiofrequency ablation of a pancreatic neuroendocrine tumor. Endoscopy 2015; 47 (Suppl. 01) E600-E601
  • 28 Pai M, Habib N, Senturk H. et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015; 7: 52-59